|
1
|
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
|
Cell
|
2012
|
11.69
|
|
2
|
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
|
Sci Transl Med
|
2010
|
6.39
|
|
3
|
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
|
Nat Genet
|
2012
|
5.28
|
|
4
|
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
|
J Clin Invest
|
2009
|
5.07
|
|
5
|
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
|
Cancer Discov
|
2011
|
4.80
|
|
6
|
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
|
N Engl J Med
|
2015
|
4.78
|
|
7
|
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium.
|
J Natl Cancer Inst
|
2010
|
3.18
|
|
8
|
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
|
J Clin Oncol
|
2011
|
2.10
|
|
9
|
New non-viral method for gene transfer into primary cells.
|
Methods
|
2004
|
2.00
|
|
10
|
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
|
J Clin Oncol
|
2011
|
1.75
|
|
11
|
Benchmarking of mutation diagnostics in clinical lung cancer specimens.
|
PLoS One
|
2011
|
1.65
|
|
12
|
Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.
|
J Clin Oncol
|
2013
|
1.65
|
|
13
|
Early palliative care for patients with advanced cancer: how to make it work?
|
Curr Opin Oncol
|
2013
|
1.57
|
|
14
|
Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction.
|
Basic Res Cardiol
|
2008
|
1.52
|
|
15
|
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.
|
Mod Pathol
|
2012
|
1.50
|
|
16
|
Determinants and patient-reported long-term outcomes of physician empathy in oncology: a structural equation modelling approach.
|
Patient Educ Couns
|
2007
|
1.46
|
|
17
|
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
|
J Clin Invest
|
2013
|
1.41
|
|
18
|
Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2.
|
Int J Cancer
|
2003
|
1.41
|
|
19
|
CD74-NRG1 fusions in lung adenocarcinoma.
|
Cancer Discov
|
2014
|
1.19
|
|
20
|
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
|
Cancer Discov
|
2013
|
1.18
|
|
21
|
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
|
PLoS One
|
2008
|
1.16
|
|
22
|
Blood-based gene expression signatures in non-small cell lung cancer.
|
Clin Cancer Res
|
2011
|
1.09
|
|
23
|
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
|
J Thorac Oncol
|
2008
|
1.09
|
|
24
|
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
|
J Nucl Med
|
2011
|
1.08
|
|
25
|
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
|
Clin Pharmacokinet
|
2011
|
1.08
|
|
26
|
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
|
Eur J Nucl Med Mol Imaging
|
2012
|
1.02
|
|
27
|
Left ventricular remodeling after myocardial infarction in mice with targeted deletion of the NADPH oxidase subunit gp91PHOX.
|
Basic Res Cardiol
|
2005
|
1.02
|
|
28
|
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.
|
Genome Biol
|
2015
|
1.01
|
|
29
|
Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells.
|
Lancet Oncol
|
2004
|
1.00
|
|
30
|
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
|
Clin Pharmacokinet
|
2011
|
1.00
|
|
31
|
Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells.
|
Am J Pathol
|
2002
|
0.98
|
|
32
|
Diarrhea associated with afatinib: an oral ErbB family blocker.
|
Expert Rev Anticancer Ther
|
2013
|
0.96
|
|
33
|
[Psychometric evaluation of the German version of the "Consultation and Relational Empathy" (CARE) measure at the example of cancer patients].
|
Psychother Psychosom Med Psychol
|
2007
|
0.94
|
|
34
|
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
|
J Nucl Med
|
2009
|
0.93
|
|
35
|
The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs.
|
Am J Physiol Heart Circ Physiol
|
2005
|
0.92
|
|
36
|
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
|
Clin Nucl Med
|
2012
|
0.92
|
|
37
|
Identification of lung cancer with high sensitivity and specificity by blood testing.
|
Respir Res
|
2010
|
0.91
|
|
38
|
CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data.
|
Bioinformatics
|
2006
|
0.91
|
|
39
|
Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
|
J Thorac Oncol
|
2011
|
0.90
|
|
40
|
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
|
PLoS One
|
2013
|
0.90
|
|
41
|
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
|
J Thorac Oncol
|
2015
|
0.89
|
|
42
|
The influence of occupational stress factors on the nicotine dependence: a cross sectional study.
|
Tob Induc Dis
|
2010
|
0.85
|
|
43
|
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
|
J Clin Oncol
|
2002
|
0.85
|
|
44
|
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.
|
Clin Cancer Res
|
2004
|
0.84
|
|
45
|
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
|
J Thorac Oncol
|
2015
|
0.82
|
|
46
|
Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project.
|
Breast Care (Basel)
|
2011
|
0.82
|
|
47
|
Allelic losses on chromosome 6q25 in Hodgkin and Reed Sternberg cells.
|
Cancer Res
|
2003
|
0.81
|
|
48
|
Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
|
Eur J Haematol
|
2008
|
0.81
|
|
49
|
Reviewing the safety of erlotinib in non-small cell lung cancer.
|
Expert Opin Drug Saf
|
2010
|
0.81
|
|
50
|
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
|
J Thorac Oncol
|
2015
|
0.80
|
|
51
|
A collagen α2(I) mutation impairs healing after experimental myocardial infarction.
|
Am J Pathol
|
2011
|
0.80
|
|
52
|
A cost calculation model for specialist palliative care for patients with non-small cell lung cancer in a tertiary centre.
|
Support Care Cancer
|
2007
|
0.79
|
|
53
|
Efficient activation of autologous tumor-specific T cells: a simple coculture technique of autologous dendritic cells compared to established cell fusion strategies in primary human colorectal carcinoma.
|
J Immunother
|
2007
|
0.79
|
|
54
|
Validation of the "SmoCess-GP" instrument - a short patient questionnaire for assessing the smoking cessation activities of general practitioners: a cross-sectional study.
|
BMC Fam Pract
|
2010
|
0.78
|
|
55
|
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
|
Lung Cancer
|
2012
|
0.78
|
|
56
|
Planning impairments in schizophrenia: specificity, task independence and functional relevance.
|
Schizophr Res
|
2013
|
0.77
|
|
57
|
Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma.
|
Br J Haematol
|
2004
|
0.77
|
|
58
|
Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
|
Clin Cancer Res
|
2005
|
0.77
|
|
59
|
Rapid remineralization of multiple disseminated bone lesions after high-dose cytarabine in a patient with isolated myeloid sarcoma.
|
Eur J Haematol
|
2014
|
0.77
|
|
60
|
Proficient mismatch repair protein expression in Hodgkin and Reed Sternberg cells.
|
Int J Cancer
|
2002
|
0.76
|
|
61
|
The association between active participation in a sports club, physical activity and social network on the development of lung cancer in smokers: a case-control study.
|
BMC Res Notes
|
2012
|
0.76
|
|
62
|
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.
|
J Thorac Oncol
|
2010
|
0.76
|
|
63
|
An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591.
|
Br J Haematol
|
2002
|
0.76
|
|
64
|
Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil.
|
J Clin Psychiatry
|
2006
|
0.76
|
|
65
|
[New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology].
|
Rontgenpraxis
|
2003
|
0.75
|
|
66
|
The major subtypes of human B-cell lymphomas lack mutations in BCL-2 family member BAD.
|
Int J Cancer
|
2006
|
0.75
|
|
67
|
Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab.
|
Am J Hematol
|
2002
|
0.75
|
|
68
|
Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report.
|
J Clin Psychiatry
|
2004
|
0.75
|
|
69
|
[Current developments and perspectives in targeted therapies].
|
Onkologie
|
2010
|
0.75
|
|
70
|
[In memoriam--Franz Carmine].
|
Pharm Unserer Zeit
|
2008
|
0.75
|
|
71
|
Repeated clonal relapses in classical Hodgkin's lymphoma and the occurrence of a clonally unrelated diffuse large B cell non-Hodgkin lymphoma in the same patient.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
72
|
Personalized therapy of lung cancer.
|
Onkologie
|
2012
|
0.75
|
|
73
|
[Personalized therapy of lung cancer - current standard and future challenges].
|
Dtsch Med Wochenschr
|
2017
|
0.75
|
|
74
|
Stratified Treatment in Lung Cancer.
|
Oncol Res Treat
|
2016
|
0.75
|